首页> 外文期刊>Pharmaceutics >Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses
【24h】

Pre-Clinical and Clinical Efficiency of Complexes of Oligoribonucleotides with D-Mannitol against Respiratory Viruses

机译:寡核糖核苷酸与D-甘露醇复合物抗呼吸道病毒的临床前和临床效率

获取原文
           

摘要

Oligoribonucleotides-D-mannitol (ORNs-D-M) complexes possess antiviral, anti-inflammatory, and immunomodulatory actions. The aim of the present study was to evaluated an antiviral effect of ORNs-D-M against parainfluenza virus type 3 (PIV3); influenza CA709, PR834; avian influenza virus H5N2 (AIV) in vitro by a TCID 50 ; hemadsorption and neuraminidase activity assays; and clinical efficiency of ORNs-D-M in patients with acute respiratory infections (ARIs) of various etiologies by PCR assay and AmpliSens test systems. It was observed that ORNs-D-M have an antiviral activity against the influenza CA709, PR834, PIV3, and AIV in vitro. The injectable dosage form of ORNs-D-M was shown to have a stronger antiviral effect compared to capsule form. It was also detected that the injectable form of ORNs-D-M significantly reduced the neuraminidase activity of influenza PR834. A complex treatment of patients with ORNs-D-M had a positive effect on the course of the disease, it accelerated patients’ recovery. Treatment with ORNs-D-M caused eradication of adeno- and influenza viruses in patients with ARI. This drug contributed to significant decrease in duration of febrile period and cough. Comprehensive treatment with ORNs-D-M improved the disease clinical findings significantly. Collectively, these results suggested that ORNs-D-M may be used at co-infection with influenza and other respiratory viruses as a medical antiviral drug.
机译:寡核糖核苷酸-D-甘露醇(ORNs-D-M)复合物具有抗病毒,抗炎和免疫调节作用。本研究的目的是评估ORNs-D-M对3型副流感病毒(PIV3)的抗病毒作用。 CA709,PR834流感; TCID 50体外测定禽流感病毒H5N2(AIV);血液吸附和神经氨酸酶活性测定; PCR检测和AmpliSens测试系统检测各种病因的急性呼吸道感染(ARI)患者的ORNs-D-M的临床疗效据观察,ORNs-D-M在体外对CA709,PR834,PIV3和AIV流感具有抗病毒活性。与胶囊剂型相比,ORNs-D-M的注射剂型显示出更强的抗病毒作用。还检测到ORNs-D-M的注射形式显着降低了流感PR834的神经氨酸酶活性。对ORNs-D-M患者进行复杂的治疗可对疾病进程产生积极影响,可加快患者的康复速度。 ORNs-D-M的治疗可根除ARI患者的腺病毒和流感病毒。该药物导致发热期和咳嗽持续时间显着减少。 ORNs-D-M的综合治疗显着改善了疾病的临床表现。总体而言,这些结果表明,ORNs-D-M可以作为医学抗病毒药物与流感和其他呼吸道病毒共感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号